{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for levomethadyl root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2014)
Source URL:
First approved in 1989
Source:
NDA019684
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2021)
Source URL:
First approved in 1968
Source:
ANDA076709
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA077062
(1968)
Source URL:
First approved in 1968
Source:
ANDA077062
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA077154
(1968)
Source URL:
First approved in 1968
Source:
ANDA077154
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 338
(2017)
Source URL:
First approved in 1955
Source:
NDA202100
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091135
(2012)
Source URL:
First approved in 1948
Source:
NDA018279
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 346.18(b) anorectal:astringent witch hazel (haramelis water)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03371381: Phase 1/Phase 2 Interventional Terminated Adenocarcinoma of Lung
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
